论文部分内容阅读
老牌庄股重庆啤酒12月7日发布公告,称“治疗用(合成肽)乙型肝炎疫苗在对乙肝的疗效上与安慰剂相比并无统计学差异”。通俗的说,就是疫苗基本无效,导致重庆啤酒的股价连续7个跌停,从停牌前的83.12元/股跌到了38.76元/股。最受伤的除了股民还有一众基金,其中大成基金旗下五兄弟扎堆重啤,合计持股超过了3600万股,市值损失应在
The old Zhuangguang Chongqing Brewery December 7 announcement that “therapeutic (synthetic peptide) hepatitis B vaccine in the efficacy of hepatitis B compared with placebo no significant difference”. Ordinarily, that is, the vaccine is basically ineffective, resulting in a continuous limit of 7 shares of Chongqing Beer, down from the previous suspension of 83.12 yuan / share to 38.76 yuan / share. In addition to the most injured shareholders there are a number of funds, including Dacheng Fund’s five brothers get together heavy beer, a total of more than 3600 shares held by the stock market losses should be at